ASCO 2019: PARP-Inhibitor Achieves ‘Complete Response’ in Pancreatic Cancer
BRCA was the key to success CHICAGO — Pancreatic cancer trials don’t report complete responses,...
Read More
ASCO 2019
ASCO 2019: Studies Offer Evidence—ACA Improves Care
Too little, too late to save Obamacare? CHICAGO — As the nation prepares to once again litigate...
Read MoreASCO 2019: Multiple Myeloma Survival Linked to Income and Insurance
Zip code can be a risk factor CHICAGO – Multiple myeloma is a serious and often deadly disease, but outcomes may be better for those whose medical care is covered by private insurers. Or, it’s possible all survival, like...
Read More
ASCO 2019: ENZAMET and TITAN Are Wins in Prostate Cancer
Survival is about more than testosterone suppression CHICAGO — Men with metastatic hormone...
Read More
ASCO 2019: Metformin No Help in Advanced Prostate Cancer
Diabetes drug offers no benefit to non-diabetic patients CHICAGO – Metformin, when added to...
Read More
ASCO 2019: Ribociclib Claims First Ever Overall Survival Benefit for Targeted Therapy. MONALEESA 7 confirms CDK4/6 inhibitor efficacy in younger women
By Peggy Peck, Editor-in-Chief, BreakingMED CHICAGO — Adding the CDK4/6 inhibitor ribociclib to...
Read More
ASCO 2019: Getting on the Same Page with mCODE. ASCO unveils initiative to topple EHR ‘Tower of Babel’
CHICAGO — What if all health systems, all hospitals, and all oncologists spoke the same language —...
Read More
ASCO 2019: Pembrolizumab Changes ‘the Conversation’ in GI Cancer
Immunotherapy drug works as well as chemotherapy in advanced patients CHICAGO – In a...
Read More
ASCO 2019: Diet to Prevent Breast Cancer Death, Precision Medicine, and More
By Peggy Peck, Editor-in-Chief, BreakingMED In advance of the American Society of Clinical...
Read More- 1
- 2